SCHEMBL5334408

SCHEMBL5334408

O=C(Nc1ccc(-c2ccc(CN3CCOCC3)c3noc(Nc4ccccc4)c23)cc1)Nc1cccc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.52
FLT3 P36888 10/20 0.52
KIT P10721 7/20 0.52
IKBKE Q14164 1/20 0.48
MAPT P10636 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
PDGFRB P09619 2/20 0.45
CSF1R P07333 2/20 0.44
FLT1 P17948 2/20 0.44
TEK Q02763 1/20 0.44
MOK Q9UQ07 2/20 0.42
MTOR P42345 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5332717 0.89 KDR (0.51) KDRFLT3KITIKBKEALDH1A1
SCHEMBL1383488 0.88 KDR (0.58) KDRFLT3KITIKBKEMAPT
SCHEMBL423203 0.82 KDR (0.70) KDRFLT3KITIKBKEPDGFRB
SCHEMBL1378823 0.79 KDR (0.56) KDRFLT3KITIKBKEALDH1A1
SCHEMBL4739851 0.78 KDR (0.58) KDRFLT3KITIKBKEALDH1A1
SCHEMBL4735824 0.78 KDR (0.72) KDRFLT3KITIKBKEPDGFRB
SCHEMBL4736503 0.77 IKBKE (0.65) KDRFLT3KITIKBKEKMT2A
SCHEMBL1379304 0.74 FLT3 (0.62) KDRFLT3KITIKBKEPDGFRB
SCHEMBL422289 0.73 KDR (0.65) KDRFLT3KITIKBKEPDGFRB
SCHEMBL420485 0.72 KDR (0.81) KDRFLT3KITMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed